Bendroflumethiazide
Bendroflumethiazide by Zyntex is a high-potency thiazide diuretic and antihypertensive agent (CAS 73-48-3). It is a critical pharmaceutical active used primarily to manage hypertension and edema by inhibiting sodium reabsorption in the distal tubules of the kidney, promoting the excretion of water and electrolytes.
Description
Zyntex supplies high-purity Bendroflumethiazide (CAS 73-48-3) tailored specifically for global pharmaceutical manufacturing plants, clinical cardiovascular research laboratories, and international anti-hypertensive drug development loops.
Functioning as a highly specific sodium-chloride symporter inhibitor and metabolic diuretic agent, it delivers precise substance profiles that ensure uniform dry batch integration and highly predictable dissolution kinetics in solid-dose manufacturing matrices. Furthermore, its strictly minimized chemical volatile impurities and optimized crystal particle size geometry make it an ideal selection for sensitive oral tablet production. Accordingly, formulation scientists specify this active substance to stabilize modern cardiovascular carriers and maintain exact dosage integrity across continuous processing cycles.
Thiazide Mechanism and Diuretic Stability
Excellent crystalline solubility and outstanding ion-transport inhibition profiles provide a distinct operational edge when engineering modern fast-acting diuretic treatments. This active pharmaceutical solid operates by inhibiting the sodium-chloride symporter in the distal convoluted tubule, supplying the exact biological mechanisms required to support fluid balance and blood pressure reduction without altering raw pharmaceutical binder uniformity. It assists compounding engineers in maintaining strict dosage uniformity across high-speed compression and filling lines, mitigating trace instability risks within automated volumetric dosing machinery. For instance, specialized pharmaceutical facilities incorporate this active substance as a core component in targeted anti-hypertensive and edema-reduction tablet lines. As a consequence, it maximizes the technical throughput of automated filling machinery and continuous quality assurance checks. Consequently, Zyntex coordinates clean room crystallization paths to eliminate downstream polymorph shifts from your factory schedule.
In addition to this, Zyntex coordinates climate-controlled logistics for pilot-scale trials and advanced cardiovascular research centers. The compound maintains its refined crystalline integrity under strict storage parameters, preventing heat-induced chemical breakdown or structural degradation during automated mechanical blending steps. It advances contemporary medical engineering by providing a thoroughly analyzed, highly predictable diuretic raw material that meets international monograph standards. Simultaneously, it remains a critical chemical standard for routine high-performance liquid chromatography (HPLC) calibrations and bioanalytical validation testing assays. In brief, our product functions as a dependable chemical foundation, supporting both the performance of commercial tablet batches and the analytical rigor of specialized industrial laboratories.
Primary Medical Sectors for Bendroflumethiazide
This high-purity crystalline active drug compound delivers crucial technical value within these four primary industrial sectors:
💊 Anti-Hypertensive Tablets
Primary active pharmaceutical source used for formulating uniform, clinical-grade cardiovascular tablets. Hence, it directly supports optimal dosage control lines.
💧 Edema Management
Utilized as a high-purity active base to compound specialized fluid-reduction therapy formulations. Clearly, it is key for uniform dissolving patterns.
🔬 Chromatographic Assays
Acts as an essential reference active standard for diuretic potency metrics, assay calibration, and routine laboratory diagnostics. Resultantly, it guarantees excellent matrix clarity.
🏢 Cardiovascular Research
Used as a professional active component for validating advanced renal-pressure control models and specialized therapeutic carriers. Specifically, it confirms optimal reaction pathways.
Technical Specifications
| Parameter | Standard Value |
|---|---|
| Product Name | Bendroflumethiazide |
| Assay / Purity (HPLC) | 98.0% to 102.0% (Dry Basis) |
| Appearance | White or almost white crystalline powder |
| Melting Point | 220°C to 230°C (with decomposition) |
| Solubility | Practically insoluble in water; soluble in ethanol and acetone |
| CAS Number | 73-48-3 |
📝 Safety & Handling: Bendroflumethiazide is a potent thiazide diuretic pharmaceutical active ingredient. Direct inhalation of crystalline bulk powder dust or accidental eye/skin exposure can trigger electrolyte imbalance, localized irritation, and potential dermatological sensitivity. Therefore, store strictly inside original airtight industrial drums within a well-ventilated, dry warehouse zone protected from light, moisture, and elevated temperatures. Prevent airborne dust clouds during dispensing loops. Proper personal protective equipment (PPE)—including high-grade nitrile chemical gloves, safety glasses with side shields, and a certified dust respirator mask—must be worn during all manufacturing handling phases. Review the Safety Data Sheet (SDS).
